Research & development

In-vitro diagnostics

Lifestyle products

Chronic diseases affect over 2 billion people worldwide, representing one of the greatest threats to global societies. If these diseases continue to escalate unchecked—a scenario the UN has been warning about since 1989—not only will they overwhelm healthcare systems, but they will also disrupt markets globally and impact everyone.

 

Environmental factors contribute to harmful processes such as inflammation, which accelerate the onset and progression of chronic diseases. These processes result in damage to endothelial cells (the inner lining of blood vessels) and fibrosis (excessive growth of connective tissue). This increasing burden, particularly in developed nations, is straining healthcare systems to their limits.


Until recently, chronic diseases could only be detected after irreversible organ damage had occurred, with treatments often untargeted, delayed, and not tailored to individual needs. This is now changing. Mosaiques' proprietary proteome analysis—validated in over 100 clinical studies, involving contributions from more than 1,200 leading scientists and physicians, and published in over 400 peer-reviewed articles—enables early disease detection before irreversible organ damage occurs and supports the development of personalized, optimal treatment strategies.



Societies worldwide, along with the entire healthcare industry—including diagnostics, pharmaceuticals, and even the food sector—are facing enormous health challenges. Mosaiques' technology, which advances our understanding of proteomic mechanisms, is already tackling and addressing these challenges today.

Mosaiques' proteome analysis - the game changer in health care!

Contact

More information about our business in our presentations is available in the download center.

Download center

Company Overview

▶ Since 2002 - Headquarter: Hanover, Germany


▶ Industry: Biotechnology - Special feature "Proteome decoding" - Medicine B2C and B2B


▶ Mosaiques' unique position:

Mosaiques' proprietary proteome analysis platform has uncovered the molecular mechanisms behind non-infectious diseases, linking them to molecular pathophysiology. This approach, powered by advanced algorithms and artificial intelligence (AI), has been validated in highly regarded clinical studies, paving the way for significant advancements in medicine. The platform’s unique proteomic insights allow for the mapping of disease-related molecular changes influenced by environment, diet, and medication, resulting in continuous knowledge expansion from Mosaiques' vast proteome database—a "perpetual motion machine" for knowledge generation. Additionally, Mosaiques has established rigorous standards for acquiring comprehensive scientific knowledge of the proteome.


▶ Medical / Clinical benefits:

Diseases can now be defined at the molecular level, identified early — before organ damage — and treated in a more precise, targeted manner. Patients receive personalized treatment based on their specific proteomic profile, and this approach has been applied across all stages of disease. Depending on the exact molecular cause, different proteins (and biomarkers) are affected, and while approved drugs for the same disease may target different biomarkers, they act based on the molecular signature of the disease.

Through Mosaiques' proteome analysis, it's possible to connect specific disease biomarkers with the molecular effects of treatment. Additionally, personalized recommendations for dietary and lifestyle changes can be made to complement pharmacological interventions.

Furthermore, Mosaiques' extensive proprietary database and insights into disease-specific molecular changes facilitate more targeted and efficient drug development—at a faster pace and lower cost compared to conventional approaches.


▶ Market: 2 billion people

(In contrast: rare diseases due to genetic defects may account 10 million cases worldwide, detectable on the genome level)

Current Situation

Chronic diseases often develop without noticeable symptoms and are driven by multiple, specific changes in the proteome. At present, these conditions are typically diagnosed and treated only after significant organ damage has occurred. However, while drugs can target proteins, they cannot revive dead cells or repair damaged organs. In developed countries, the treatment of cardiovascular and kidney diseases, along with cancer, consumes over 50% of healthcare resources, costs, and personnel.



Mosaiques’ technology is set to transform health management by shifting the focus from "repairing damage" to "preserving health."

Mosaiques' Unique Position

For the first time, Mosaiques' advanced proteome biomarkers define the multiple disease-specific molecular changes that both trigger and drive chronic diseases. These same proteome changes are also keys to disease progression. In-vitro diagnostics for cardiovascular and kidney diseases, as well as certain cancers, have already been approved for clinical use in Germany and are now being marketed.


Mosaiques' precision proteome biomarkers provide a comprehensive view of the molecular pathophysiology underlying specific diseases. These biomarkers reveal the molecular mechanisms driving disease at an individual level, reflecting different causes and predicting the outcomes of specific interventions. This is precision medicine delivered through personalized diagnostics via the proteome!


This approach also revolutionizes drug development by enabling targeted identification of drug candidates, reducing development time, risks, and costs. Additionally, the disease-specific human proteome can be translated into mouse models, improving drug testing and minimizing costs associated with development.


Currently, Mosaiques is developing new drugs for bladder cancer, with candidates in pre-clinical and early-stage (Phase I/II) clinical trials. In the food sector, their technology has demonstrated the positive effect of olive oil on cardiovascular health.

Study Evidence and Publications since 2002

Since 2002, over 100 clinical, evidence-based studies have been conducted in collaboration with more than 1,200 leading doctors and scientists from 85 university hospitals around the globe. These studies have resulted in over 400 peer-reviewed publications, many of which were funded by the European Commission and featured in top-tier scientific journals.


The extensive research conducted across a wide range of chronic disease areas has consistently demonstrated significant clinical benefits associated with Mosaiques’ proteome analysis technology. These studies have provided strong evidence of its effectiveness in early disease detection, individualized treatment strategies, and improved patient outcomes. This body of work has firmly established Mosaiques' technology as a transformative tool in precision medicine, helping to shape the future of healthcare and offering new insights into the molecular mechanisms underlying various diseases.



The breadth of these publications highlights the global recognition and scientific credibility of the Mosaiques approach, positioning it at the forefront of advancements in both diagnostics and personalized therapeutics.

Societal Impact

The United Nations has recognized chronic diseases as a threat to humanity on par with Ebola, highlighting their potential to severely disrupt global health. With demographic changes placing increasing pressure on Western healthcare systems, there is a real risk of collapse.


Diet (including contaminated food sources), environmental factors, and lifestyle choices all influence proteins, making a deep understanding of proteomic mechanisms essential to human health. This knowledge will serve as the foundation for future medical advancements.



The paradigm shift enabled by insights into the proteome has the potential to significantly reduce the burden of chronic diseases. It will transform healthcare by shifting the focus away from managing organ damage and slowing disease progression, towards more preventive, cost-effective, and less resource-intensive approaches. Ultimately, this breakthrough will lead to substantial improvements in the quality and sustainability of healthcare systems worldwide.

Mosaiques' Proteome Analysis:

The Foundation of Precision Medicine!

Proteomics - the understanding of molecular mechanisms and disease-specific biomarkers - is revolutionizing the entire landscape of healthcare and the preservation of human health. Until recently, the specific mechanisms by which drugs affected individual patients were largely unknown. Medications were developed and prescribed without a comprehensive understanding of the complex proteomic changes involved in disease. Since drugs only target specific proteins, they address limited aspects of a disease, such as heart failure, which only affects certain patients. Other drugs target different proteins within the same disease, which may be driven by a different underlying cause.


Previously, there was no ability to tailor molecular therapies or develop treatments based on the complex, disease-specific proteomic biomarkers, which were previously unknown. As a result, without an understanding of the proteome, drugs were effective in only 15-30% of patients. Chronic diseases, traditionally diagnosed after organ damage had occurred, could not be cured, and treatment often only slowed disease progression in a small percentage of cases.


Through Mosaiques' advanced proteome analysis, chronic diseases can now be detected before organ damage occurs. This allows for precisely targeted treatments, which can prevent organ damage and deliver significantly better outcomes for patients.

Benefits of Clinical Proteomics

The scientific axiom is:


"Proteins, not genes, are the direct determinants of life's functions!"


  1. Proteins, in fact, bridge the genome and the environment. They can analyze factors such as diet, physical exercise, and inflammation caused by particulate matter in the environment—essentially everything that affects the body through their interaction. This enables the determination of both the causes of their changes and the effects of medication alone. This was not possible before!
  2. Approximately one-quarter of this information comes from genes, while three-quarters come from the environment.
  3. Proteins are responsible for the development of diseases in approximately 2 billion people, including those caused by genetic defects, which affect about 10 million people. Even genetic mutations, such as those in a tumor, exert their effects only through the altered proteins.
  4. The uniqueness of mosaiques' proteome analysis lies in its innovative combination of capillary electrophoresis coupled with mass spectrometry and artificial intelligence, enabling the technology to reach its full potential.
Introduction into proteome analysis

Unique, Proprietary Database and AI

Mosaiques has developed a unique, highly specialized proteome database, built from over 100 clinical studies involving more than 85,000 samples. This database contains detailed patient histories and tracks disease progression, with millions of individual protein measurements. This wealth of data, combined with the robustness and validity of Mosaiques' proprietary technology, serves as the foundation for identifying biomarkers for various conditions. These discoveries are often made through collaborations (B2B), as highlighted on the platform www.power-of-proteomics.com. The quality and patient benefits of the proteomic data have been consistently demonstrated in evidence-based studies across multiple disease areas, and, to date, no other protein analysis method (B2C) has shown comparable patient benefit.


Proteome analysis, which involves studying the complete set of proteins in the body, is primarily conducted using body fluids like urine - considered the "filtrate of the blood." The results are compared against disease-specific proteomes validated in clinical studies, using AI-driven analysis based on Mosaiques' extensive proteome database. The findings are then displayed in a pseudo-3D format, providing the basis for precise diagnosis and personalized treatment based on each individual’s unique proteome.

Drug Discovery and Evaluation

We developed an approach that will radically transform and accelerate drug development and implementation in a personalized manner. This is accomplished trough an innovative pipeline that utilizes an artificial intelligence (AI) based approach. Our pipeline builds on scientific and technological breakthroughs and AI algorithms to integrate high resolution multi-omics data. By this we enable rational selection of drug candidates based on underlying pathophysiology with emphasis on drugs already approved for different context-of-use.


The implementation of our technology is possible from the very beginning of preclinical development (animal models) to the point of phase III or rather phase IV clinical trials. We are highly experienced in the efficient and time-saving assessment of newly developed as well as already existing pharmaceutical substances. Our approach in clinical proteomics enables the accurate clinical characterisation of patients and controls (high fidelity phenotyping). Proteome profiling will accelerate drug development by ascertainment of statistically significant data from a small number of patients (defined cohorts) plus an enhancement in the determination of pharmaceutical drug safety.


Disease state specific proteome patterns help to select an appropriate therapy. Therapeutic effects of administered drug can be displayed and controlled in the proteome patterns. This enables optimization of applied therapy (e.g. dosage modification).

Beyond Disease: The Proteome Reveals Biological Age

Proteome analysis offers a deeper understanding of the body, serving as a mosaic that illustrates the complex internal processes and structures. At the molecular level, it can determine a person’s biological age, which reflects age-related changes such as tissue degradation. This biological age is closely linked to conditions like cardiovascular and kidney diseases, which are tied to specific molecular patterns known as the "aging proteome."


The aging proteome represents a molecular intersection for many diseases, providing valuable insights into chronic conditions and the aging processes that drive them. By detecting imbalances early, the proteome can identify diseases in their formative stages, enabling timely interventions that prevent further deterioration and improve overall health outcomes.

If you are interested in innovative solutions to address the rapidly growing health challenges facing developed countries and would like to get involved, please register for access to additional information available on the password-protected page*:

Further Details

*You will receive the password by contacting us via the contact form.

Joachim Conrads

  Joachim Conrads is the founder and legal advisor of mosaiques diagnostics and therapeutics AG (MDAG). He has studied law and philosophy and is an internationally active investor. His achievements were honored with the “Golden Nose” award for the Business Angel of the Year 2002. He has long-standing expertise in law, IPR, finances, as well as marketing.

Prof. Dr. Dr. Harald Mischak

Professor Harald Mischak is co-founder of Mosaiques diagnostics and therapeutics AG (2002), which was  started with the aim to identify disease-specific peptides. With more than 400 scientific publications on signaling and proteomics that have been cited over 37000 times (h-index in Google 106), he is one of the leading experts worldwide in the field of proteome research, personalized medicine, and applied systems biology.

Share by: